76 related articles for article (PubMed ID: 22342917)
1. Combining bacterial-immunotherapy with therapeutic antibodies: a novel therapeutic concept.
Klier U; Maletzki C; Kreikemeyer B; Klar E; Linnebacher M
Vaccine; 2012 Apr; 30(17):2786-94. PubMed ID: 22342917
[TBL] [Abstract][Full Text] [Related]
2. Antibody-based therapy in colorectal cancer.
Noguchi T; Ritter G; Nishikawa H
Immunotherapy; 2013 May; 5(5):533-45. PubMed ID: 23638747
[TBL] [Abstract][Full Text] [Related]
3. The potential role of immunotherapy to treat colorectal cancer.
Amin M; Lockhart AC
Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074
[TBL] [Abstract][Full Text] [Related]
4. Avitalized bacteria mediate tumor growth control via activation of innate immunity.
Klier U; Maletzki C; Göttmann N; Kreikemeyer B; Linnebacher M
Cell Immunol; 2011; 269(2):120-7. PubMed ID: 21463858
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.
Yang Y; Guo Q; Xia M; Li Y; Peng X; Liu T; Tong X; Xu J; Guo H; Qian W; Hou S; Dai J; Wang H; Liu R; Guo Y
MAbs; 2015; 7(2):440-50. PubMed ID: 25679409
[TBL] [Abstract][Full Text] [Related]
6. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of Colorectal Cancer.
Jäger D; Halama N; Zörnig I; Klug P; Krauss J; Haag GM
Oncol Res Treat; 2016; 39(6):346-50. PubMed ID: 27259331
[TBL] [Abstract][Full Text] [Related]
9. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
Yoon J; Koo KH; Choi KY
Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
[TBL] [Abstract][Full Text] [Related]
10. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.
Staib L; Birebent B; Somasundaram R; Purev E; Braumüller H; Leeser C; Küttner N; Li W; Zhu D; Diao J; Wunner W; Speicher D; Beger HG; Song H; Herlyn D
Int J Cancer; 2001 Apr; 92(1):79-87. PubMed ID: 11279610
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in human colorectal cancer: Challenges and prospective.
Sun X; Suo J; Yan J
World J Gastroenterol; 2016 Jul; 22(28):6362-72. PubMed ID: 27605872
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy for colorectal cancer].
Tougeron D; Fauquembergue É; Latouche JB
Bull Cancer; 2013 Sep; 100(9):871-85. PubMed ID: 23917703
[TBL] [Abstract][Full Text] [Related]
14. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
[TBL] [Abstract][Full Text] [Related]
15. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
16. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
17. Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96.
Pilla L; Squarcina P; Coppa J; Mazzaferro V; Huber V; Pende D; Maccalli C; Sovena G; Mariani L; Castelli C; Parmiani G; Rivoltini L
Cancer Res; 2005 May; 65(9):3942-9. PubMed ID: 15867395
[TBL] [Abstract][Full Text] [Related]
18. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic Approaches for the Treatment of Colorectal Cancer.
Abakushina EV; Gelm YV; Pasova IA; Bazhin AV
Biochemistry (Mosc); 2019 Jul; 84(7):720-728. PubMed ID: 31509724
[TBL] [Abstract][Full Text] [Related]
20. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
